ReviewBlood neoplasia2026
Co-option of lineage plasticity as a hallmark of multipotent acute leukemias.
Review in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Leukemias are classified by hematopoietic lineage and genetic alterations. Mixed-lineage and biphenotypic leukemias have long challenged diagnostic classification because of the coexpression of markers of distinct lineages. Recent studies have revealed previously unappreciated multilineage potential in a subset of B-cell acute lymphoblastic leukemias (B-ALL) as well as leukemias with markers of myeloid and T-cell differentiation with shared genetic features variably classified as acute myeloid leukemia, early T-cell progenitor ALL, or T/myeloid mixed-phenotype acute leukemias. We propose that co-option of stem cell plasticity programs can be used to classify these as multipotent acute leukemias (MAL). Based on the urgent need for improved diagnostic and therapeutic strategies, we review the latest evidence and propose new ways to diagnose and treat MAL as distinct types of acute leukemias.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.